• Welcome to FZATA
  • News & Events

    Press Releases

    • Research article on FZ002 was published in Science Translational Medicine

      November 6, 2020

      Our first-in-class yeast based immunotherapy for C. diff infection was recently published in the Science Translational Medicine. The novelty and great potential of our platform and product have been reported by Science magazine, BioTechScope and MedicalExpress etc. https://lnkd.in/ePh5ef2 https://lnkd.in/ea2nWva https://lnkd.in/eAKhtdK

      Read More

    • FZata received SBIR Fast-track grant.

      August 1, 2020

      FZata received a SBIR Fast-track grant from NIAID to support the development of our oral immunotherapy candidate for CDI.

      Read More

    • FZata is spotlighted!

      July 31, 2020

      FZata is spotlighted by EAGB. Click here for more details.

      Read More

    • BioBuzz Newsletter- June 2019

      May 27, 2020

      Five Companies That Are Powering The Cell and Gene Therapy Revolution “Maryland companies are making a global impact in the field of cell and gene therapy” click on the link above to read more about other local companies.

      Read More

    • FZata the Recipient of Two Additional SBIR Grants in 2018!

      February 8, 2018

      Read More

    • FZata Honored as Best Life Sciences Company 2017

      December 28, 2017

      FZata is selected as the 2017 Maryland Incubator Company of the Year, Best Life Sciences Company! Way to go, FZata!

      Read More

    • FZata Selected as a Finalist for the 2017 Maryland Incubator Company of the Year Awards

      December 28, 2017

      FZata is selected as one of three Finalists in Life Science catergory for the 2017 Maryland Incubator Company of the Year Awards: http://www.mdincubatoraward.com/

      Read More

    • FZata Wins RO1 Grant.

      June 1, 2017

      FZata was awarded a 5-year RO1 grant from NIAID with totally more than $7 million dollars to develop our leading multi specific antibody candidate against CDI.

      Read More

    • FZata Received NIH SBIR Funding

      January 1, 2017

      FZata was awarded Small Business Innovation Research (SBIR) Phase I grant from National Institute of Health (NIH) to develop treatment against Clostridium difficile infection (CDI).

      Read More

    • FZata Receives NIH U19 Grant Subaward

      April 28, 2016

      As subawardee of University of Maryland, Baltimore, FZata, Inc. received NIH grant support in 2016 to develop threapies against Clostridium difficile infection.

      Read More